Clinical Trials Directory

Trials / Unknown

UnknownNCT03760172

Immunomediated Non-alcoholic SteaTohepatitis; Prevalence and Characterization. INSTInCT Study

Status
Unknown
Phase
Study type
Observational
Enrollment
7,300 (estimated)
Sponsor
Instituto de Investigación Marqués de Valdecilla · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

NAFLD is a common comordidity in patients with IMID, including inflammatory bowel disease and psoriasis. Nevertheless, the prevalence of NAFLD and NASH in the IMID population is not clear, and the risk factors are not completely understood. Interestingly, NASH and most of IMIDs share main molecular and immunological mechanisms of disease, as the inflammatory pathways depending on TNFa or imbalance in T cell subtypes like Th17/Treg. This common pathogenesis may explain, at least in a subset of patients, the development of NASH in the absence of classic metabolic risk factor. Thus, our main hypothesis is that in the NASH assciated to IMIDs two different phenotypes co-exist. First, a predominantly inflammatory phenotype, and not associated to the metabolic syndrome ande second, a predominantly metabolic phenptype, strongly associated to he metabolic syndrome. In this way, we believe that in a particular subset of NAFLD patients, NASH could be considered as an IMID, as most of the definiting features of IMIDs are present. To demonstrate our hypothesis, we consider a two-stage study. First, we will determine the NAFLD and NASH prevalence in a cohort of well-characterized IMID patients and controls. Second, we will adress the molecular and immunophenotype characterization in liver biopsies of NASH patients with and without the co-existence of IMIDs.

Conditions

Timeline

Start date
2019-01-07
Primary completion
2020-12-31
Completion
2021-12-31
First posted
2018-11-30
Last updated
2018-11-30

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT03760172. Inclusion in this directory is not an endorsement.